Effect of the combination of the dual mTOR/pI3K inhibitor NVP-BEZ235 with gemcitabine on growth inhibition in pancreatic cancer cells in vitro and in vivo

被引：0
|
作者：
Maute, Luise
Wicht, Johannes
Zoernig, Martin
Niederhagen, Manuel
Bergmann, Lothar
机构：
[1] Univ Hosp, Med Clin 2, Frankfurt, Germany
[2] Goethe Univ Frankfurt, D-60054 Frankfurt, Germany
[3] Georg Speyer Haus, Inst Biomed Res, Frankfurt, Germany
[4] Goethe Univ Frankfurt, Senckenberg Inst Pathol, D-60054 Frankfurt, Germany
[5] Dept Med, Frankfurt, Germany
[6] Univ Canc Ctr Frankfurt, Frankfurt, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15070
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Combination strategy of gemcitabine with the dual PI3K/mTOR inhibitor NVP-BEZ235 in pancreatic cancer cells.
    Hausmann, E.
    Glienke, W.
    Bergmann, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] The combination of gemcitabine with the dual PI3K/mTOR-inhibitor NVP-BEZ235 in human pancreatic cancer cell lines
    Glienke, W.
    Hausmann, E.
    Wicht, J.
    Maute, L.
    Bergmann, L.
    [J]. ONKOLOGIE, 2011, 34 : 57 - 58
  • [3] Radiosensitization by the Dual PI3K/mTOR inhibitor NVP-BEZ235
    Cerniglia, George J.
    Karar, Jayashree
    Koumenis, Constantinos
    Maity, Amit
    [J]. CANCER RESEARCH, 2012, 72
  • [4] Radiosensitization by the Dual PI3K/mTOR Inhibitor NVP-BEZ235
    Maity, A.
    Cerniglia, G. J.
    Karar, J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S84 - S85
  • [5] Effect of NVP-BEZ235, a dual PI3K/mTOR inhibitor, on chemotherapy and antiangiogenic response in pancreatic cancer
    Ostapoff, Katherine T.
    Awasthi, Niranjan
    Yen, Peter L.
    Zhang, Changhua
    Schwarz, Margaret A.
    Brekken, Rolf A.
    Schwarz, Roderich
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [6] Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines
    Masuda, Mitsuhiro
    Shimomura, Manami
    Kobayashi, Ken
    Kojima, Shuji
    Nakatsura, Tetsuya
    [J]. ONCOLOGY REPORTS, 2011, 26 (05) : 1273 - 1279
  • [7] NVP-BEZ235, A Dual PI3K/mTOR Inhibitor, Enhances Chemotherapy and Antiangiogenic Response in Pancreatic Cancer
    Ostapoff, K. T.
    Awasthi, N.
    Yen, P. L.
    Zhang, C.
    Schwarz, M. A.
    Brekken, R. A.
    Schwarz, R. A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S46 - S46
  • [8] SYNTHESIS AND PROCESS OPTIMIZATION OF PI3K/MTOR DUAL INHIBITOR NVP-BEZ235
    Xu, T. S.
    Lei, F.
    Tao, H.
    Li, J. Q.
    Zhang, Z. W.
    Wang, L. X.
    Xu, S.
    Zheng, P. W.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 119 : 31 - 31
  • [9] Inhibition of Autophagy as a Strategy to Augment Radiosensitization by the Dual PI3K/mTOR Inhibitor NVP-BEZ235
    Maity, A.
    Cerniglia, G. J.
    Karar, J.
    Koumenis, C.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S127 - S127
  • [10] Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy
    Lin, Shu-Fu
    Huang, Yu-Yao
    Lin, Jen-Der
    Chou, Ting-Chao
    Hsueh, Chuen
    Wong, Richard J.
    [J]. PLOS ONE, 2012, 7 (10):
12345